Skip to main content

Table 4 Costs and utilities per 9-week Markov cycle for each model state

From: Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer

State Combination arm Monotherapy arm
Cost/8 week ($) QALY/8 week Cost/8 week ($) QALY/8 week
Stable disease 793,432.000 0.11076923 407,540.000 0.11230769
Treatment complication 801,398.177 0.11076923 410,717.085 0.11230769
Progression 00 0.09076923 0 0.09076923
Progression with complication 7966.17746 0.09076923 3177.08511 0.09076923
Death 0 0 0 0